Biotech Strategy Blog

Commentary on Science, Innovation & New Products

About MaverickNY

Here are my most recent posts

Posts by MaverickNY

Top 10 AML abstracts at ASH 2014

San Francisco Milan Trolley 200x300 Top 10 AML abstracts at ASH 2014San Francisco – Acute Myeloid Leukemia (AML) is largely a disease of the elderly since it is uncommon before the age of 45. It generally has a much poorer prognosis compared to other leukemias such as CML and even ALL. There are two main treatment options – high chemotherapy (ara-C is the main bedrock) or a stem cell transplant in those patients who are considered eligible. With the average age at diagnosis being ~66yo, many patients may be elderly and frail, making a SCT not a viable option.

Leave a comment

EORTC Molecular Targets – new developments in Ovarian Cancer

Ovarian cancer is an often neglected area in cancer drug development and historically has often been one of the last solid tumours to be evaluated as part of a life cycle management program. There are a number of reasons for this, but recently that situation has begun to change as our knowledge of the underlying biology improves and new agents are developed that target the particular oncogenic aberrations.

Leave a comment